Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H19ClN2 |
Molecular Weight | 310.8212 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
c1cc2CCc3cc(ccc3C(=C4CCNCC4)c2nc1)Cl
InChI
InChIKey=JAUOIFJMECXRGI-UHFFFAOYSA-N
InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2
Molecular Formula | C19H19ClN2 |
Molecular Weight | 310.8212 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11243504Curator's Comment:: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11243504
Curator's Comment:: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf
Desloratadine is an active, descarboethoxy metabolite of loratadine. It acts by selective inhibition of H1 histamine receptor and thus provides relief to patients with allergic rhinitis and chronic idiopathic urticaria. Desloratadine was approved by FDA and it is currently marketed under the name Clarinex (among the others).
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 |
0.87 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | CLARINEX Approved UseDesloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria. Launch Date1.00889277E12 |
|||
Palliative | CLARINEX Approved UseDesloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria. Launch Date1.00889277E12 |
|||
Palliative | CLARINEX Approved UseDesloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria. Launch Date1.00889277E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4 ng/mL |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DESLORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
56.9 ng × h/mL |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DESLORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
27 h |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DESLORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
84.5% |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DESLORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1.25 mg 1 times / day steady, oral Dose: 1.25 mg, 1 times / day Route: oral Route: steady Dose: 1.25 mg, 1 times / day Sources: Page: p. 25 |
unhealthy, 2-11 years n = 48 Health Status: unhealthy Age Group: 2-11 years Sex: M+F Population Size: 48 Sources: Page: p. 25 |
Disc. AE: Somnolence, Abdominal pain... AEs leading to discontinuation/dose reduction: Somnolence (1 patient) Sources: Page: p. 25Abdominal pain (1 patient) |
45 mg 1 times / day multiple, oral Highest studied dose Dose: 45 mg, 1 times / day Route: oral Route: multiple Dose: 45 mg, 1 times / day Sources: |
healthy, adult Health Status: healthy Age Group: adult Sex: M+F Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abdominal pain | 1 patient Disc. AE |
1.25 mg 1 times / day steady, oral Dose: 1.25 mg, 1 times / day Route: oral Route: steady Dose: 1.25 mg, 1 times / day Sources: Page: p. 25 |
unhealthy, 2-11 years n = 48 Health Status: unhealthy Age Group: 2-11 years Sex: M+F Population Size: 48 Sources: Page: p. 25 |
Somnolence | 1 patient Disc. AE |
1.25 mg 1 times / day steady, oral Dose: 1.25 mg, 1 times / day Route: oral Route: steady Dose: 1.25 mg, 1 times / day Sources: Page: p. 25 |
unhealthy, 2-11 years n = 48 Health Status: unhealthy Age Group: 2-11 years Sex: M+F Population Size: 48 Sources: Page: p. 25 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
likely | ||||
likely | ||||
likely | no (pharmacogenomic study) Comment: pharmacogenotype 2C19 does not correlate with systemic exposure Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=19 Page: 19.0 |
|||
likely | no (pharmacogenomic study) Comment: lack of correlation in between 2D6 genotype and 3-OH DCL formation Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10 Page: 10.0 |
|||
likely | weak (co-administration study) Comment: Coadministration of ketonconazole, mean drug Cmax and AUC0-24 values at steady state were increased by 29-45% and 21-39%, respectively; Coadministration with erythromycin, mean drug Cmax and AUC 0-24 at steady state were increased by 24% and 14%, respectively. Page: 10.0 |
|||
Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 1.0 |
yes | |||
yes | weak (co-administration study) Comment: Coadministration of ketonconazole, mean drug Cmax and AUC0-24 values at steady state were increased by 29-45% and 21-39%, respectively; Coadministration with erythromycin, mean drug Cmax and AUC 0-24 at steady state were increased by 24% and 14%, respectively. |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice. | 2000 Apr 29 |
|
[The effect of second generation histamine antagonists on the heart]. | 2001 |
|
Desloratadine: a new approach in the treatment of allergy as a systematic disease--pharmacology and clinical overview. Introduction. | 2001 |
|
Desloratadine in the treatment of chronic idiopathic urticaria. | 2001 |
|
Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. | 2001 |
|
Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. | 2001 |
|
Applications of new liquid chromatography-tandem mass spectrometry technologies for drug development support. | 2001 Aug 10 |
|
[Urticaria. Finally undisturbed sleep]. | 2001 Jul 26 |
|
Chronic idiopathic urticaria treatment. | 2001 Jul-Aug |
|
Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. | 2001 Mar |
|
Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation. | 2001 Mar |
|
In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. | 2001 Sep |
|
Mediator antagonists in the treatment of allergic disease. | 2001 Sep-Oct |
|
Second-generation antihistamines in asthma therapy: is there a protective effect? | 2002 |
|
Poor sleep and daytime somnolence in allergic rhinitis: significance of nasal congestion. | 2002 |
|
Advances in allergy management. | 2002 |
|
Impact and modulation of nasal obstruction. | 2002 |
|
Investigation of an enhanced resolution triple quadrupole mass spectrometer for high-throughput liquid chromatography/tandem mass spectrometry assays. | 2002 |
|
A pharmacokinetic profile of desloratadine in healthy adults, including elderly. | 2002 |
|
Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. | 2002 |
|
24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]. | 2002 Aug 5 |
|
Treatment of allergic rhinitis. | 2002 Dec 16 |
|
Are antihistamines useful in managing asthma? | 2002 Feb |
|
Desloratadine (Clarinex). | 2002 Mar 18 |
|
Gateways to clinical trials. | 2002 May |
|
Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. | 2002 Nov |
|
Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. | 2002 Oct |
|
Severe hepatotoxicity after application of desloratadine and fluconazole. | 2003 |
|
Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. | 2003 Apr |
|
Pharmacokinetic properties of single-dose loratadine and ambroxol alone and combined in tablet formulations in healthy men. | 2003 Aug |
|
Gateways to clinical trials. | 2003 Dec |
|
Interactions of olopatadine and selected antihistamines with model and natural membranes. | 2003 Dec |
|
Comparative in vivo bioactivity of modern H1-antihistamines on AMP challenge in atopic asthma. | 2003 Feb |
|
The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study. | 2003 Jan 6 |
|
Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma. | 2003 Jul |
|
Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. | 2003 Mar |
|
[Multicenter study of the effectiveness and tolerability of desloratadine in seasonal allergic rhinitis]. | 2003 May 25 |
|
Desloratadine for allergic rhinitis. | 2003 Nov 15 |
|
A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitis. | 2003 Oct |
|
Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment. | 2003 Oct |
|
Reliable and specific high-performance liquid chromatographic method for simultaneous determination of loratadine and its metabolite in human plasma. | 2003 Oct 25 |
|
[Modern antihistaminics against allergic rhinitis. Better breathing without side effects]. | 2003 Oct 30 |
|
Improvements in simulated real-world relevant performance for patients with seasonal allergic rhinitis: impact of desloratadine. | 2004 Apr |
|
Inhibition of cold urticaria by desloratadine. | 2004 Jan |
|
Anti-inflammatory activity of H1-receptor antagonists: review of recent experimental research. | 2004 Jan |
|
Gateways to clinical trials. | 2004 Jan-Feb |
|
High-performance liquid chromatographic method for the bioequivalence evaluation of desloratadine fumarate tablets in dogs. | 2004 Mar 10 |
Patents
Sample Use Guides
Adults and Adolescents 12 Years of Age and Over:
take 5 mg tablet once daily. Children 6 to Years of Age: take 2.5 mg tablet once daily. Children 12 Months to 5 Years of Age: take 1.25 mg tablet once daily. Children 6 to 11 Months of Age: 1 mg tablet once daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7677235
Nasal epithelial cells (activated by 1 uM of histamine) were treated with 10 uM of desloratadine and the inhibitory activity of the drug on expression of ICAM-1 and HLA-DR was studied.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:08:37 UTC 2021
by
admin
on
Fri Jun 25 21:08:37 UTC 2021
|
Record UNII |
FVF865388R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
DESLORATADINE TEVA (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
||
|
LIVERTOX |
284
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
||
|
WHO-VATC |
QR06AX27
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
OPULIS (WITHDRAWN: RHINITIS, URTICARIA)
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
||
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
||
|
NDF-RT |
N0000175587
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
ALLEX(WITHDRAWN: RHINITIS, ALLERGIC, SEASONAL)
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
DASSELTA (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
DESLORATADINE RATIOPHARM (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
DESLORATADINE ACTAVIS (AUTHORIZED: RHINITIS, URTICARIA)
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
AZOMYR (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
||
|
WHO-ATC |
R06AX27
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
AERINAZE (AUTHORIZED: RHINITIS)
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
AERIUS(AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
NEOCLARITYN (AUTHORIZED: RHINITIS, URTICARIA)
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
||
|
NDF-RT |
N0000000190
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1370280
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
PRIMARY | USP-RS | ||
|
1173042
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
PRIMARY | USP-RS | ||
|
CHEMBL1172
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
PRIMARY | |||
|
DB00967
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
PRIMARY | |||
|
C121345
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
PRIMARY | |||
|
7817
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
PRIMARY | |||
|
275635
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
PRIMARY | RxNorm | ||
|
100643-71-8
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
PRIMARY | |||
|
Desloratadine
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
PRIMARY | |||
|
C47474
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
PRIMARY | |||
|
124087
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
PRIMARY | |||
|
814
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
PRIMARY | |||
|
FVF865388R
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
PRIMARY | |||
|
Desloratadine
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
PRIMARY | |||
|
7157
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
PRIMARY | |||
|
M4193
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
PRIMARY | Merck Index | ||
|
SUB01596MIG
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
PRIMARY | |||
|
100643-71-8
Created by
admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TRANSPORTER -> INHIBITOR |
Ki
|
||
|
METABOLIC ENZYME -> NON-INHIBITOR | |||
|
METABOLIC ENZYME -> NON-INHIBITOR | |||
|
BINDER->LIGAND |
BINDING
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> NON-INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> INHIBITOR |
WEAK
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> INHIBITOR |
WEAK
|
||
|
TARGET -> INHIBITOR |
Kd
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> INHIBITOR |
WEAK
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> NON-INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
PARENT -> METABOLITE ACTIVE |
MAJOR
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
DOSE |
|
||
Biological Half-life | PHARMACOKINETIC |
|
|
|||